Biden's Proposal Boosts Novo Nordisk Shares Amid Obesity Drug Debate
Novo Nordisk's shares rose due to President Joe Biden's proposal to expand Medicare and Medicaid coverage for anti-obesity drugs. While current rules exclude obesity-specific drugs, this proposal could lower costs and increase access.
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Wall Street Journal on MSN2d
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionNovo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
COPENHAGEN (Reuters) -Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden ...
22hon MSN
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback